Earnings call transcript: Dr. Reddy’s Q4 2026 revenue misses forecast By Investing.com

Dr. Reddy’s Q4 FY2026 revenue came in at $849 million versus $893 million expected, a 4.9% miss, while premarket shares fell 5.52% to $12.65. The shortfall was driven by lower lenalidomide sales after patent expiry, partially offset by double-digit growth in the base business and record FY2026 annual revenue. Management guided to gross margins above 50% in FY2027, supported by semaglutide launches, product mix improvements, and cost efficiencies.

Analysis

The key market implication is not the one-quarter miss; it is the forced re-rating of the post-lenalidomide earnings bridge. The market had implicitly assumed a cleaner handoff to the next growth leg, but the call exposed that North America is still much more dependent on a narrow set of products than headline diversification suggests. That makes the stock vulnerable to a multiple compression regime until investors see two or three quarters of proof that semaglutide, biosimilars, and the newer U.S. launches can offset erosion faster than expected.

The more interesting second-order effect is that semaglutide is now the de facto sentiment catalyst for the entire company, but its monetization path is more complex than a simple launch ramp. Management’s own commentary implies a staggered rollout across markets, with some geographies delayed and pricing dispersion wide enough to make near-term revenue less linear than bulls likely modeled. In other words, the market may be overestimating how quickly semaglutide turns into clean EBITDA leverage while underestimating the working-capital and commercialization drag that comes with multi-market expansion.

On the competitive side, the weakness in one incumbent generic franchise is a reminder that the North American generics complex remains a low-visibility, price-erosion business unless a product has real scarcity. That is constructive for the few names with differentiated pipelines, but it also means the rebound in RDY could lag peers that have cleaner U.S. contribution mixes or less exposure to one-product cliffs. The contrarian angle: the selloff may be too focused on the quarter and not enough on the company’s ability to finance a higher-quality mix shift with cash on hand and limited balance-sheet strain.

Key Decisions for Investors

• Short RDY on strength for a 1-3 month horizon if the stock rallies back into pre-miss levels; risk/reward favors fading the multiple until semaglutide monetization becomes visible in reported numbers.
• Pair trade: long NVO / short RDY for 2-4 months if you want to express relative winner vs. lagging follow-through in GLP-1 commercialization; RDY has more execution risk, NVO has the cleaner demand signal.
• Buy RDY downside protection via 3-6 month puts or put spreads rather than outright shorting if you expect volatility around launch timing and biosimilar FDA milestones; the gap risk is asymmetric on positive approval headlines.
• For event-driven accounts, use RDY as a trade only after the next quarter confirms whether gross margin can hold above 50%; until then, the risk/reward is skewed by product-mix noise, not durable earnings power.